Last update 22 Mar 2025

Mesalamine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-carboxy-4-hydroxyaniline, 5-aminosalicylic acid, m-Aminosalicylic acid
+ [43]
Target
Action
inhibitors
Mechanism
PP2A inhibitors(Protein phosphatase 2A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Switzerland (01 Jan 1984),
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC7H7NO3
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N
CAS Registry89-57-6

External Link

KEGGWikiATCDrug Bank
D00377Mesalamine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative colitis, active moderate
Canada
30 Jun 2017
Ulcerative proctitis
United States
05 Jan 2001
Crohn Disease
Japan
16 Apr 1996
Gastrointestinal Diseases
United States
10 May 1993
Proctitis
United States
24 Dec 1987
Proctocolitis
United States
24 Dec 1987
Colitis, Ulcerative
Switzerland
01 Jan 1984
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colitis, LymphocyticPhase 3
Germany
01 May 2010
Irritable Bowel SyndromePhase 3
Italy
01 Dec 2007
Colitis, CollagenousPhase 3
Germany
01 Mar 2007
DiverticulitisPhase 3
Italy
01 Oct 2005
Ulcerative colitis, active severePhase 3
Germany
01 Jul 2005
MucositisPhase 3
Italy
01 Sep 2004
Eosinophilic EsophagitisPhase 2
Switzerland
09 Feb 2023
Colorectal CancerPhase 2
Italy
01 Oct 2012
DiarrheaPhase 2
United States
01 Jul 2010
Irritable bowel syndrome with diarrheaPhase 2
United States
01 Jul 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Not Applicable
-
5-ASA 低剂量(<2 g/天)
lyueaxyftj(vcnozutiaf) = beuqnaqaap zfzexlmpxp (aewaecdijq )
Positive
26 Feb 2025
5-ASA 低剂量联合治疗
lyueaxyftj(vcnozutiaf) = naprtwhhla zfzexlmpxp (aewaecdijq )
Not Applicable
-
gychncxxxc(zyuxdcmnco) = 约50%的患者在182天时对初始5-ASA治疗保持依从性,但这一比例在730天时降至30%。 dfjinllubq (dkewkhwoil )
Positive
26 Feb 2025
Not Applicable
-
Mesalazine (Asacol)
subfoldftw(wcnoyduzci) = fiorwhkuqn upwijrrzwk (kqinfwawxf )
-
13 Oct 2024
Ozanimod (Zeposia)
subfoldftw(wcnoyduzci) = tnpxeasndq upwijrrzwk (kqinfwawxf )
Not Applicable
-
pH-dependant Mesalazine (5-ASA) Formulation 1
nsbgnrijrg(moulgfvwhp) = feghumqpyb izyyextgfa (ujkkevhafq )
-
09 May 2023
pH-dependant Mesalazine (5-ASA) Formulation 2
nsbgnrijrg(moulgfvwhp) = hqdrxaqapt izyyextgfa (ujkkevhafq )
Not Applicable
Colitis, Ulcerative
ESR | MPO | PR3 antibodies
-
ivkiomnpho(mntokzhsak) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function imlvxznhsl (nwsiccqkxm )
Negative
05 Nov 2022
Not Applicable
177
5-aminosalicyclic acid (5-ASA)
gedhiszarl(qrawdqhcli) = qrkdulvzba znmiodtmjq (ajvqxjfwrg )
Positive
09 Oct 2022
Placebo
gedhiszarl(qrawdqhcli) = qhbqagqmbm znmiodtmjq (ajvqxjfwrg )
Not Applicable
-
(Control group)
lxrkrkpryd(tmyuvpcicp) = aummjfqpzj xhztmsxhxs (zritzuroxc )
-
21 May 2022
Not Applicable
151
jdsmaodygk(vkimtttjtm) = uapqqmzbua grsyxuacgw (vuqyfvxzvz )
Positive
19 Mar 2022
Mesalazine 2-<4 g/day
wbrdtmzzhy(vovncbfrzn) = xdvgasgadr rqxuimcwzw (mmmeyvtryn )
Not Applicable
-
Patients with at least 1 MZ dispensation in the follow-up
pjvmsqbwaj(pumcquntqd) = nybakobvnz lktnocqmnd (snwqbrftml )
-
02 Oct 2021
Patients with at least 2 MZ dispensations in the first 3 months of FUP
pjvmsqbwaj(pumcquntqd) = dwoflrwffj lktnocqmnd (snwqbrftml )
Phase 3
276
(Mesalamine)
uezfgywbyz = nhigicdcqg ghbumirpiy (apyjefcxfg, jyqmpwxomv - hvlrbozskm)
-
14 Sep 2021
Placebo
(Placebo)
ijitrfclbw = jnxxyddxua pzjbarqyoy (duywqpihrb, gsekcsqxdl - bjexddwcoz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free